Supernus Pharmaceuticals Current Ratio 2011-2024 | SUPN
Supernus Pharmaceuticals current ratio from 2011 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Supernus Pharmaceuticals Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$0.64B |
$0.29B |
2.20 |
| 2024-06-30 |
$0.59B |
$0.31B |
1.92 |
| 2024-03-31 |
$0.54B |
$0.32B |
1.73 |
| 2023-12-31 |
$0.49B |
$0.29B |
1.70 |
| 2023-09-30 |
$0.45B |
$0.29B |
1.56 |
| 2023-06-30 |
$0.42B |
$0.25B |
1.68 |
| 2023-03-31 |
$0.88B |
$0.73B |
1.21 |
| 2022-12-31 |
$0.73B |
$0.69B |
1.07 |
| 2022-09-30 |
$0.66B |
$0.73B |
0.91 |
| 2022-06-30 |
$0.63B |
$0.74B |
0.85 |
| 2022-03-31 |
$0.57B |
$0.29B |
2.00 |
| 2021-12-31 |
$0.60B |
$0.32B |
1.91 |
| 2021-09-30 |
$0.67B |
$0.24B |
2.85 |
| 2021-06-30 |
$0.64B |
$0.28B |
2.26 |
| 2021-03-31 |
$0.59B |
$0.24B |
2.43 |
| 2020-12-31 |
$0.63B |
$0.25B |
2.57 |
| 2020-09-30 |
$0.55B |
$0.30B |
1.84 |
| 2020-06-30 |
$0.56B |
$0.27B |
2.07 |
| 2020-03-31 |
$0.56B |
$0.17B |
3.31 |
| 2019-12-31 |
$0.47B |
$0.16B |
2.94 |
| 2019-09-30 |
$0.43B |
$0.15B |
2.85 |
| 2019-06-30 |
$0.39B |
$0.14B |
2.72 |
| 2019-03-31 |
$0.42B |
$0.15B |
2.77 |
| 2018-12-31 |
$0.49B |
$0.16B |
3.06 |
| 2018-09-30 |
$0.39B |
$0.14B |
2.82 |
| 2018-06-30 |
$0.29B |
$0.10B |
2.74 |
| 2018-03-31 |
$0.58B |
$0.12B |
4.90 |
| 2017-12-31 |
$0.23B |
$0.12B |
1.86 |
| 2017-09-30 |
$0.19B |
$0.11B |
1.82 |
| 2017-06-30 |
$0.17B |
$0.09B |
1.94 |
| 2017-03-31 |
$0.15B |
$0.08B |
1.83 |
| 2016-12-31 |
$0.15B |
$0.08B |
1.88 |
| 2016-09-30 |
$0.14B |
$0.07B |
1.93 |
| 2016-06-30 |
$0.11B |
$0.07B |
1.69 |
| 2016-03-31 |
$0.09B |
$0.06B |
1.69 |
| 2015-12-31 |
$0.11B |
$0.06B |
1.86 |
| 2015-09-30 |
$0.10B |
$0.04B |
2.35 |
| 2015-06-30 |
$0.11B |
$0.04B |
2.89 |
| 2015-03-31 |
$0.10B |
$0.03B |
3.69 |
| 2014-12-31 |
$0.11B |
$0.03B |
3.87 |
| 2014-09-30 |
$0.10B |
$0.02B |
4.65 |
| 2014-06-30 |
$0.07B |
$0.02B |
3.75 |
| 2014-03-31 |
$0.08B |
$0.03B |
2.95 |
| 2013-12-31 |
$0.10B |
$0.03B |
3.68 |
| 2013-09-30 |
$0.10B |
$0.03B |
4.10 |
| 2013-06-30 |
$0.11B |
$0.02B |
6.90 |
| 2013-03-31 |
$0.08B |
$0.03B |
2.83 |
| 2012-12-31 |
$0.09B |
$0.02B |
3.98 |
| 2012-09-30 |
$0.06B |
$0.03B |
2.56 |
| 2012-06-30 |
$0.08B |
$0.02B |
3.56 |
| 2012-03-31 |
$0.04B |
$0.02B |
1.93 |
| 2011-12-31 |
$0.05B |
$0.02B |
2.63 |
| 2011-09-30 |
$0.00B |
|
0.00 |
| 2011-06-30 |
$0.00B |
|
0.00 |
| 2011-03-31 |
$0.00B |
|
0.00 |
| 2010-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
